Open an account

BioCardia

BCDA · NASDAQ

$1.04+$0.1425 (+15.88%)TodayMarket closed ·
Prev close $0.8975

About BCDA

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company is headquartered in Sunnyvale, California and currently employs 17 full-time employees. The company is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

Employees
17
Headquarters
Sunnyvale, California
Listed
Nov 13, 1996
Sector
Health Care
Industry
Biotechnology
Website
biocardia.com

BCDA key statistics

Market cap
15.74M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
254.40K
Volume
217.71K
Open price
$0.90
High today
$1.07
Low today
$0.90
52 Week high
$1.80
52 Week low
$0.75

BioCardia (BCDA) at a glance

As of Oct 20, 2026, BioCardia (BCDA) shares are priced at $1.04, giving the company a market cap of 15.74M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.90 and $1.07. The current price is 15.6% above the day's low and 2.8% below its high.

Volume so far is 217.71K shares, in line with the average of 254.40K shares a day.

Over the past year BioCardia has ranged from $0.75 to $1.80, and now sits 28% of the way up that range.

BioCardia met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.13 per share against an estimate of -$0.1836.

The average analyst price target is $15.81, 1420.2% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $15.81
Low
$6.06
Now
$1.04
High
$26.25

BCDA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 45.3% on average.

  1. Q3 FY24: reported -$0.61 per share against an estimate of -$1.21
  2. Q4 FY24: reported -$0.25 per share against an estimate of -$0.6375
  3. Q1 FY25: reported -$0.59 per share against an estimate of -$0.3978
  4. Q2 FY25: reported -$0.40 per share against an estimate of -$0.51
  5. Q3 FY25: reported -$0.24 per share against an estimate of -$0.2346
  6. Q4 FY25: reported -$0.06 per share against an estimate of -$0.1734
  7. Q1 FY26: reported -$0.21 per share against an estimate of -$0.1683
  8. Q2 FY26: reported -$0.13 per share against an estimate of -$0.1836

BCDA news

  • Tanya Rawat

    BioCardia Shares Fall 10% After Hours: Here's Why

  • Kaustubh Bagalkote

    What's Going On With BioCardia Stock Tuesday?

  • Vandana Singh

    Why Is BioCardia Stock Gaining Friday?

  • BioCardia Q1 2026 Earnings Call: Complete Transcript

  • Earnings Outlook For BioCardia

  • Avi Kapoor

    Gold Falls Over 1%; Darden Posts Downbeat Earnings

  • Avi Kapoor

    Nasdaq Surges 100 Points; Bionano Genomics Shares Plunge

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

Similar companies

Companies in the same industry as BioCardia

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.